氯唑西林与头孢唑林治疗甲氧西林敏感金黄色葡萄球菌菌血症(CloCeBa):一项前瞻性、开放标签、多中心、非劣效性、随机临床试验
在法国21家医院开展的前瞻性、开放标签、非劣效性随机试验中,315例甲氧西林敏感金黄色葡萄球菌菌血症成人患者随机接受头孢唑林或氯唑西林治疗,主要终点头孢唑林组109/146(75%)vs 氯唑西林组108/146(74%),治疗差异-1%(95%CI -11至9;p=0.012),达到非劣效性;头孢唑林组严重不良事件22/146(15%)vs 氯唑西林组40/146(27%)(p=0.010),急性肾损伤氯唑西林组15/128(12%)vs 头孢唑林组1/134(1%)(p=0.0002)。
要点
- 头孢唑林治疗MSSA菌血症第90天临床成功率75%,氯唑西林为74%,达到非劣效性。
- 头孢唑林组严重不良事件发生率15%,低于氯唑西林组的27%。
- 急性肾损伤在氯唑西林组更常见(12% vs 1%)。
核心结论
- 头孢唑林可作为氯唑西林治疗MSSA菌血症的替代选择,临床疗效非劣效且可能耐受性更佳。
研究设计与样本
- 在法国21家大学与非大学医院开展的前瞻性、开放标签、非劣效性、随机临床试验。
- 纳入年龄≥18岁、无血管内植入物或中枢神经系统感染疑似的MSSA菌血症成人患者。
- 参与者按1:1随机接受头孢唑林(25-50 mg/kg 每8小时静脉给药)或氯唑西林(25-50 mg/kg 每4-6小时静脉给药)治疗前7天,后续治疗由研究者选择(总疗程≥14天)。
- 主要终点为第3天(心内膜炎为第5天)血培养无菌且无菌血症复发、生存及第90天临床成功的复合终点,在意向治疗人群中评估,非劣效界值为12%。
- 2018年9月5日至2023年11月16日共入组315例,头孢唑林组158例、氯唑西林组157例,排除后每组各146例进入分析。
主要发现
- 主要终点达到率:头孢唑林组109/146(75%)vs 氯唑西林组108/146(74%),治疗差异-1%(95%CI -11至9;p=0.012)。
- 治疗结束时严重不良事件:头孢唑林组22/146(15%)vs 氯唑西林组40/146(27%)(p=0.010)。
- 急性肾损伤:氯唑西林组15/128(12%)vs 头孢唑林组1/134(1%)(p=0.0002)。
- 平均年龄62.7岁(SD 16.4),男性215例(74%),未收集种族或族裔数据,中位Pitt评分0(IQR 0-0)。
临床怎么用
- 作者认为头孢唑林可作为氯唑西林治疗MSSA菌血症的替代选择,临床疗效非劣效且可能耐受性更佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although widely used, cefazolin efficacy for the treatment of meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia has not thus far been investigated in a clinical trial. In this study, we aimed to compare the efficacy and safety of cefazolin with that of cloxacillin in patients with MSSA bacteraemia. METHODS: We conducted an open-label, non-inferiority, randomised clinical trial in 21 university and non-university hospitals in France in adults (aged ≥18 years) with MSSA bacteraemia, without intravascular implant or suspicion of CNS infection. Participants were randomly assigned (1:1) to receive intravenously cefazolin (25-50 mg/kg every 8 h) or cloxacillin (25-50 mg/kg every 4-6 h) for the first 7 days of therapy using computer-generated blocks of various sizes and stratification on vascular-access associated bacteraemia and centre. Subsequent treatment was left to the choice of the investigator (total duration ≥14 days). The primary endpoint was a composite of sterile blood cultures at day 3 (day 5 for endocarditis) without relapse of bacteraemia, survival, and clinical success at day 90, and was assessed in the intention-to-treat population. A non-inferiority margin of 12% was chosen. This trial is registered on ClinicalTrials.gov (NCT03248063) and is complete. FINDINGS: Between Sept 5, 2018, and Nov 16, 2023, 315 participants were enrolled and assigned to cefazolin (n=158) or cloxacillin (n=157); 12 participants were excluded from analysis in the cefazolin group, and 11 in the cloxacillin group (final population of 146 in each group). Mean age was 62·7 years (SD 16·4), 215 (74%) participants were male, and race or ethnicity data were not collected. Median Pitt score was 0 (IQR 0-0). The primary endpoint was met in 109 (75%) of 146 participants in the cefazolin group versus 108 (74%) of 146 participants in the cloxacillin group (treatment difference -1%; 95% CI -11 to 9; p=0·012). At the end of study treatment, 22 (15%) of 146 participants assigned to cefazolin and 40 (27%) of 146 participants assigned to cloxacillin had had a serious adverse event (p=0·010). Acute kidney injury occurred more frequently in participants assigned to cloxacillin (15 [12%] of 128) than in those assigned to cefazolin (one [1%] of 134; p=0·0002). INTERPRETATION: Cefazolin constitutes an alternative to cloxacillin for the treatment of MSSA bacteraemia, offering non-inferior clinical efficacy and potentially enhanced tolerability. FUNDING: French Ministry of Health.
引用
- Burdet C, Saïdani N, Dupieux C, et al. Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial. Lancet. 2025. PMID: 41115439. doi:10.1016/S0140-6736(25)01624-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。